Godavari Biorefineries Limited, through its clinical-stage biotech division Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA) for its innovative anti-cancer molecule, HYDROXY-1,4-NAPHTHALENEDIONE. The achievement strengthens the company’s intellectual property portfolio and advances its efforts in life sciences innovation.
A New Class of Compounds Targeting Cancer
The patented molecule represents a novel class of compounds. In preclinical in vitro studies, these compounds have shown strong inhibitory effects on cancer and cancer stem cells. Early research has demonstrated significant efficacy against multiple cancer types, including breast and prostate cancers. These findings point to its potential as a promising therapy in oncology.
Commitment to High-Impact Research
Dr. Sangeeta Srivastava, Executive Director of Godavari Biorefineries Limited, emphasized, “Our commitment to original, high-quality science drives our journey beyond green chemistry into life sciences. This Chinese patent strengthens the promise of our lead molecule and highlights the vital work our team at Sathgen Therapeutics does to develop innovative therapies for some of the world’s most pressing medical needs.”
Strengthening Global Reach in Life Sciences
Godavari Biorefineries has built a robust international presence, exporting to over twenty countries and actively collaborating with global R&D networks. Through Sathgen Therapeutics, the company is spearheading next-generation cancer and antiviral therapies, with its lead molecule already undergoing clinical trials. As per the press release, the milestone marks a critical step in translating cutting-edge research. It brings impactful healthcare solutions to patients worldwide.
